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ABSTRACT
Introduction. 4-Aminopyridine (fampridine), a potassium channel blocker, has demonstrated efﬁcacy in improving
lower extremity strength and walking speed in patients with multiple sclerosis. Since in vitro electrophysiologic
studies are recommended for evaluating a drug’s potential to prolong the QT interval and induce such cardiac
arrhythmias as Torsades de Pointes, we examined the electrophysiologic effects of 4-aminopyridine (0.5, 5.0, 50, and
500 mM) on isolated canine Purkinje ﬁbers.
Methods. Microelectrodes monitored the resting membrane potential, overshoot, amplitude of action potential
(AP), and maximal rate of depolarization of the AP upstroke in Purkinje ﬁbers stimulated at 0.5 and 1.0 Hz.
Results. None of the above variables were altered in the presence of 4-aminopyridine. The AP duration at 30%,
50%, and 90% repolarization was also monitored, with only the 500-mM concentration at the 1.0-Hz frequency
signiﬁcantly increasing these values with respect to baseline (P < 0.05). However, the small sample size (N = 4) was
small. The proportional increases, and their 95% conﬁdence intervals, were 90.8% (-36.4%, 218.0%), 25.8%
(11.9%, 39.7%), and 22.0% (14.9%, 29.1%) for APD 30%, 50%, and 90% repolarization, respectively. Reverse rate
dependence was not observed, suggesting inhibition of ion channels other than those contributing to QT interval
prolongation.
Key Words. Fampridine; 4-Aminopyridine; Purkinje Fibers; Action Potential; Cardiac Effects; Torsades de Pointes
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.
interscience.wiley.com/authorresources/onlineopen.html
Introduction
A
delay in cardiac repolarization induced by
non-antiarrhythmic drugs can result in the
development of Torsades de Pointes, a potentially
fatal cardiac arrhythmia that has led to the with-
drawal of several drugs from the market [1,2].
Since prolongation of the cardiac QT interval is a
frequent precursor of Torsades de Pointes, QT
interval prolongation is recognized as a surrogate
marker for a drug’s proarrhythmic risk [1,3].
Assessment of the QT interval is recommended
by the International Conference on Harmonisa-
tion [4] and by the US Food and Drug Admin-
istration for new drugs, as well as for approved
drugs when new indications, dosages, or routes
of administration have been introduced [3].
However, since clinical assessment of QT interval
is considered to be a less than optimal method
for identifying cardiac risk [1,3], nonclinical
methods to assess the human ether-à-go-go
related gene (hERG) channel inhibition, prolon-
gation of action potential (AP) and/or QT pro-
longation in experimental animals are
recommended as part of the preclinical evalua-
tion process [5].
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gation and induction of Torsades de Pointes
inhibit hERG [6,7], the gene that encodes the
rapid delayed rectiﬁer potassium current (IKr) that
is responsible for repolarization of the cardiac
myocyte ventricular AP [2,8,9]. However, the elec-
trophysiology of the ventricular AP involves the
function of other cardiac ionic currents that could
potentially modulate the effects of hERG block-
ade. Consequently, evaluation of AP parameters
complements other techniques for assessing a
drug’s potential for cardiac toxicity.
Cardiac Purkinje ﬁbers are physiologically
appropriate for these types of studies, since these
ﬁbers conduct cardiac impulses to the ventricles
and are responsible for the early afterdepolariza-
tions that not only are associated with long QT
syndrome, but that also occur upon exposure to
drugs that prolong cardiac repolarization [10–13].
In particular, canine Purkinje ﬁbers have become
an accepted model for investigating the effects of
pharmaceutical compounds on action potential
duration (APD) because of their sensitivity to
agents that demonstrate prolongation of APD
[14–16]. Studies have suggested that drug-induced
prolongation of the AP in canine Purkinje ﬁbers
correlates with a drug’s ability to induce a clini-
cally relevant increase in human QT interval that
may be predictive of Torsades de Pointes [14,15].
4-Aminopyridine (fampridine) is a potassium
channel blocker that signiﬁcantly improves
walking speed relative to placebo in a proportion
of patients with multiple sclerosis [17–20]. The
proposed mechanism of action is a dose-
dependent blockade of voltage-gated potassium
channels that occurs at clinically relevant concen-
trations (0.2 to 2 mM; 18 to 180 ng/mL) [21,22].
As suggested in vitro using demyelinated axons, the
observed clinical effects with 4-aminopyridine
occur as a result of an increased ratio between the
action current generated by the impulse and the
minimum amount of action current needed to
maintain axonal conduction across demyelinated
internodes [23]. Additionally, 4-aminopyridine
enhances neurotransmission in intact neurons,
possibly by increasing calcium inﬂux at presynap-
tic sites [24]; however, the role of this effect as a
contributory factor to the clinical efﬁcacy of the
agent is unclear.
Since 4-aminopyridine affects potassium chan-
nels, it is important to evaluate the cardiac safety of
the agent with respect to changes in AP that could
result in arrhythmias and Torsades de Pointes.
As part of the drug evaluation process for
4-aminopyridine and in accordance with recent
guidelines, preclinical testing of 4-aminopyridine
was undertaken to determine the potential of the
agent for inducing clinically signiﬁcant QT pro-
longation. A previous preclinical study that evalu-
ated the in vitro effects of 4-aminopyridine on the
hERG channel current expressed in a human cell
line reported a low potential of the drug for QT
interval prolongation [25]. In the current study, we
evaluated the ability of 4-aminopyridine to alter
the AP parameters of isolated canine Purkinje
ﬁbers, which can also provide an indication of its
ability to induce QT prolongation.
Methods
The study protocol was reviewed and approved by
the Institutional Animal Care and Use Committee.
This study was performed in accordance with the
current guidelines for animal welfare (Animal
Welfare Act, the Guide for the Care and Use of
Laboratory Animals, and the Ofﬁce of Laboratory
Animal Welfare). The study center is registered
with the US Department of Agriculture (USDA)
andisfullyaccreditedbytheAssociationforAssess-
mentandAccreditationofLaboratoryAnimalCare
International; all animals were individually housed
in compliance with USDA guidelines.
Adult male beagle dogs (N = 5) ranging in
weight from 7.0 to 10.0 kg, obtained from Mar-
shall Farms (North Rose, NY, USA), were housed
individually and provided food up to 400 g/day
and water ad libitum until use. At the time of
experimentation, animals were anesthetized with
sodium pentobarbital and euthanized by cardiac
excision. After removal of the heart, Purkinje ﬁber
bundles were dissected from the left or right ven-
tricle. Individual Purkinje ﬁbers, each from a dif-
ferent experimental animal, were then isolated and
mounted in a recording chamber with continuous
perfusion of oxygenated (95% O2/5% CO2)
Tyrode’s solution (NaCl 125 mM, KCl 4 mM,
NaHCO3 25 mM, MgCl2 1 mM, NaH2PO4
1.2 mM, CaCl2 1.8 mM, glucose 5.5 mM) at a rate
of approximately 5 mL/minute. The bath tem-
perature was maintained at 35°C to 38°C and the
pH at 7.3 to 7.5.
The ﬁbers were electrically stimulated at 1.0 Hz
using bipolar silver electrodes, and each Purkinje
ﬁber was impaled with a KCl (3M) ﬁlled glass
microelectrode (resistance range, 16 to 26 MW)t o
monitor transmembrane potential. Purkinje ﬁbers
were allowed to equilibrate for 60 minutes to
achieve stable AP prior to experimentation. The
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using an Axoclamp-2B ampliﬁer (Axon Instru-
ments; Union City, CA, USA) with a Notocord-
hem 3.4 data capture system (Notocord Systems;
Croissy sur Seine, France). The recorded AP
parameters included resting membrane potential
(RMP); overshoot (OS); amplitude of AP (APA);
maximal rate of depolarization of the AP upstroke
(Vmax); and APD at 30%, 50%, and 90% repolar-
ization (APD30, APD50, and APD90, respectively).
Following the establishment of stable AP, pre-
treatment control values at 1.0 Hz were deﬁned by
insertion of an event marker, pacing frequency was
reduced to 0.5 Hz, and another event marker was
inserted to deﬁne the pretreatment control values
after stabilization at 0.5 Hz. Pacing frequency was
then returned to 1.0 Hz, and the ﬁbers were
equilibrated with 4-aminopyridine 0.5 mM for at
least 25 minutes, with measurement of electro-
physiologic responses subsequently recorded at
1.0 and 0.5 Hz (5 to 10 minutes). The process was
repeated for 4-aminopyridine 5 mM, 50 mM, and
500 mM, with ﬁnal ﬂushing and washout to evalu-
ate recovery. Each ﬁber was evaluated separately,
as indicated above.
Individual parameter data are presented as
the mean ( standard error [SE]) of AP values
recorded from all ﬁbers during a 60-second period
following the corresponding event marker. Since
each ﬁber served as its own control, changes in
APD30, APD50, and APD90 can be expressed as
percent change from baseline. Analysis of variance,
followed by Tukey’s HSD (honestly signiﬁcant dif-
ference) Multiple Comparison Test, was used to
compare treatment effects with control values
(Systat version 9.01; Systal Software, Inc.,
Chicago, IL); P values  0.05 were considered sta-
tistically signiﬁcant.
Results
Four Purkinje ﬁbers were used to evaluate the
effect of 4-aminopyridine on AP; a ﬁfth ﬁber was
not used because of unstable AP recordings asso-
ciated with microelectrode impalement problems.
Table 1 and Figure 1 present the mean values for
APA, OS, RMP, and Vmax for all fampridine con-
centrations at 0.5 and 1 Hz, and Table 2 shows
the corresponding mean values for APD30, APD50,
and APD90. The concentration effect, or dose
response, curves are presented in Figure 2.
At the 1.0-Hz stimulation frequency, there
appeared to be a dose-dependent increase in APD
at 5, 50 and 500 mM at all three repolarization
thresholds (30%, 50%, and 90%) (Figure 1a).
However, only the 4-aminopyridine 500-mM con-
centration resulted in increased AP durations that
were statistically signiﬁcant (P < 0.05). As shown
in Figure 1b, the proportional increases from base-
line (95% conﬁdence intervals) for the 500 mM
concentration were 90.8% (-36.4%, 218.0%),
25.8% (11.9%, 39.7%), and 22.0% (14.9%,
29.1%) for APD30, APD50, and APD90, respec-
tively. Although similar increases compared with
baseline were observed at the 0.5-Hz stimulation
frequency (Figure 2), 98.8% (-75.9%, 273.5%),
20.5% (4.9%, 36.1%), and 18.1% (2.5%, 33.7%)
higher than baseline values for APD30, APD50, and
APD90, respectively. Some dose-dependency
was observed with respect to the effect of
4-aminopyridine on APD at the 0.5-Hz frequency,
especially at the lower 4-aminopyridine concen-
trations, but this effect was not as marked as at
1.0 Hz.
Representative tracings of the AP triggered by
ﬁeld stimulation at 1.0 Hz in an isolated control
Purkinjeﬁberundercontrolconditions(Figure 3a)
and after the addition of 4-aminopyridine 500 mM
(Figure 3b) demonstrate slowing of repolarization,
with an increase in the height of the plateau and a
signiﬁcantly prolonged AP relative to the control.
Discussion
This study reports the effects of 4-aminopyridine
on the AP in a small sample size of isolated dog
Table 1 Mean (standard error) values of action potential parameters in isolated dog Purkinje ﬁbers at 1.0 and 0.5 Hz
Treatment (N)
RMP (mV) OS (mV) APA (mV) Vmax (mV/ms)
1 Hz 0.5 Hz 1 Hz 0.5 Hz 1 Hz 0.5 Hz 1 Hz 0.5 Hz
Control (4) -97.4  1.5 -94.4  1.7 31.5  0.6 31.5  0.6 129.0  1.5 125.9  2.1 658.4  70.0 657.5  69.5
Fampridine 0.5 mM (4) -96.7  1.5 -90.7  1.2 31.5  1.0 30.8  1.4 128.3  2.1 121.6  1.9 700.0  92.6 616.6  51.9
Fampridine 5 mM (4) -96.0  1.5 -90.5  2.6 28.4  0.5 27.5  1.3 124.3  1.8 118.0  3.7 612.8  70.8 584.1  83.5
Fampridine 50 mM (4) -97.1  1.3 -92.7  0.4 27.0  2.0 26.6  3.1 124.2  2.7 119.3  2.9 630.7  76.5 611.9  70.3
Fampridine 500 mM (4) -97.1  1.7 -91.3  1.5 26.5  3.9 27.9  3.9 123.6  5.4 119.2  5.2 566.3  87.1 570.3  81.5
Washout -98.1  1.0 -95.1  1.0 28.1  2.4 28.6  2.5 126.2  3.2 123.7  3.4 588.1  55.2 600.3  55.4
APA = amplitude of action potential; OS = overshoot; RMP = resting membrane potential; Vmax = maximal rate of depolarization of the action potential upstroke.
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Arch Drug Info 2010;3:19–25Purkinje ﬁbers. A signiﬁcant effect was observed
at 500 mM 4-aminopyridine (P < 0.05), and an
apparent dose-dependent increase was observed
in APD30 at 0.5, 5.0, and 50 mM. An increase
could potentially be attributed to the effects of
4-aminopyridine on the transient outward potas-
sium current (Ito). In Kenyon and Gibbons’ [26]
early work on action potential and membrane
currents in sheep Purkinje cells, they reported
that 4-aminopyridine at concentrations between
0.01 and 0.5 mM slowed the rate of phase 1 repo-
larization and shifted the plateau of the action
potential to less negative potentials. These effects
were attributed to a 4-aminopyridine-sensitive
component of the early outward current. It was
subsequently shown that the Ito of canine cardiac
Purkinje cells is inhibited by 4-aminopyridine
within the range of concentrations used in the
current study, with a reported IC50 (half maximal
[50%] inhibitory concentration) of 50 mM [27]. A
study of 4-aminopyridine in a canine model
reported that even at the maximum plasma con-
centration that was achieved in vivo by drug infu-
sion (250 uM), ventricular and atrial Ito were not
signiﬁcantly affected [28]. Studies characterizing
repolarizing currents in cardiac Purkinje cells
from other species (sheep and rabbit) have also
reported an effect of 4-aminopyridine on the Ito,
albeit at higher 4-aminopyridine concentrations
(0.5 to 2.0 mM) [29,30], possibly due to interspe-
cies differences in the ion channels. However, Ito
is primarily associated with early phase 1 repolar-
ization [31] and, although it is a key regulator of
this phase of ventricular repolarization, it does
not affect the total APD of canine ventricular
myocytes, and thus does not contribute to the
critical end point of T wave or ventricular APD
dispersion [32].
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Figure 1 Effect of 4-aminopyridine on action potential duration (APD) at 30% (APD30), 50% (APD50), and 90% (APD90)
repolarization. Data expressed as mean percent of control values ( 95% conﬁdence interval). (a) 1.0-Hz stimulation
frequency; (b) 0.5-Hz stimulation frequency.
Table 2 Mean (standard error) values of action potential duration (APD) at 30% (APD30), 50% (APD50), and 90%
(APD90) repolarization in isolated dog Purkinje ﬁbers at 1.0 and 0.5 Hz
Treatment (n)
APD30 (ms) APD50 (ms) APD90 (ms)
1 Hz 0.5 Hz 1 Hz 0.5 Hz 1 Hz 0.5 Hz
Control (4) 118.5  32.0 124.2  40.2 242.1  26.2 276.5  33.8 319.6  22.6 367.6  28.8
Fampridine 0.5 mM (4) 118.6  29.9 114.1  32.4 237.6  24.9 259.3  30.7 310.6  21.4 349.2  23.4
Fampridine 5 mM (4) 153.0  31.0 148.6  33.1 250.8  28.6 267.2  32.1 323.9  26.5 361.5  32.5
Fampridine 50 mM (4) 180.2  34.2 193.5  42.1 269.3  31.7 293.2  41.7 342.2  29.7 373.6  38.9
Fampridine 500 mM (4) 192.1  27.7 186.7  29.1 303.5  31.4 331.5  38.5 390.0  28.2 434.5  39.0
Washout 176.0  26.4 191.1  32.0 266.8  22.8 296.3  26.4 340.6  22.8 381.8  27.9
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role of 4-aminopyridine and APD in Purkinje
ﬁbers and other cardiac tissue. Sridhar et al [33]
demonstrated that 4-aminopyridine at 50 and
100 mM signiﬁcantly prolonged APD in canine
ventricular myocytes at APD50 and 90 (1 Hz), and
voltage clamp experiments suggested that a
4-aminopyridine-sensitive rapidly activating
plateau outward current is present in left ventricu-
lar canine myocytes. However, regional distinc-
tions at the molecular level in canine repolarizing
currents may explain differences in cellular
responsiveness; for example, under voltage clamp
conditions, phenylephrine had no effect on Ito in
canine epicardial myocytes, whereas Purkinje cell
Ito was inhibited by the same treatment [34].
4-aminopyridine 500 mM signiﬁcantly in-
creased the APD at all three polarization levels,
but only at the 1.0-Hz stimulation frequency
although numerically the changes with 0.5-Hz
were of similar magnitude. The rapidly activating
component of the IKr is not the only the primary
outward current responsible for initiation of ﬁnal
AP repolarization in canine ventricular muscle and
Purkinje ﬁbers [35], but its inhibition is a common
cause of AP prolongation leading to the develop-
ment of Torsades de Pointes [7,36,37].
The major channel protein of IKr is encoded by
hERG, which is primarily responsible for the ﬁnal
repolarization phases of the ventricular AP [2,8,9].
When this gene is stably transfected into an
expression system, such as human embryonic
kidney cells, expression of hERG produces a
current with the same characteristics of IKr [38].
Since many of the drugs associated with induction
of Torsades de Pointes have also been reported to
inhibit hERG [6,7], it is important to note that
our results are consistent with an in vitro study
showing that inhibition of hERG channel current
in stably transfected human embryonic kidney
cells was concentration-dependent between
4-aminopyridine concentrations of 0.3 and 30 mM
[25]. However, two factors need to be considered
in determining the clinical relevance of the in vitro
effects of 4-aminopyridine. The ﬁrst factor is that
reverse rate dependence—that is, loss of effect at
greater frequency, which is characteristic of most
drugs that predominantly block the IKr repolariz-
ing current—was not observed in the current
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gests that inhibition of ion channels other than
hERG may contribute to the 4-aminopyridine-
associated AP prolongation. The second factor is
that drugs associated with Torsades de Pointes
generally inhibit hERG at concentrations approxi-
mating therapeutic plasma concentrations [7].
Average plasma concentrations range from
0.243  0.113 mM during steady state at the
therapeutic dose of 10 mg twice daily to
0.974  0.451 mM at four times the therapeutic
dose [18].
A limitation of the study is that the analysis was
based solely on the measurement of the AP param-
eters without measurement of current. The small
sample size is a further limitation of this study that
should be considered when interpreting the
results. No a priori power calculations were per-
formed; however, post hoc it would appear that
with a sample size of 4, the power to detect a
signiﬁcant difference in APD change of approxi-
mately 65% was 70%. The lack of statistical sig-
niﬁcance for some of the analyses may reﬂect
inter-preparation variability that may have been
accentuated by the small sample size. Neverthe-
less, this in vitro electrophysiologic study suggests
that 4-aminopyridine resulted in AP prolongation
in a small sample of canine Purkinje ﬁbers. A
larger sample size would better deﬁne the concen-
tration effect relationship.
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